SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

10 Aug 2023 Evaluate
With no major difference for the quarter endedJune 2023 , the total revenue stood at Rs. 14887.10  millions.The Company has registered profit of Rs. 1665.80  millions for the quarter ended June 2023, a growth of 18.93%  over Rs. 1400.70 millions millions achieved in the corresponding quarter of last year.Operating profit surged to 3406.90 millions from the corresponding previous quarter of 2729.50 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 14887.10 14783.10 0.70 14887.10 14783.10 0.70 58146.20 54383.00 6.92
Other Income 431.60 179.30 140.71 431.60 179.30 140.71 1111.90 529.20 110.11
PBIDT 3406.90 2729.50 24.82 3406.90 2729.50 24.82 10230.40 12910.00 -20.76
Interest 307.60 68.00 352.35 307.60 68.00 352.35 439.20 72.40 506.63
PBDT 3099.30 2661.50 16.45 3099.30 2661.50 16.45 9791.20 12837.60 -23.73
Depreciation 603.50 547.60 10.21 603.50 547.60 10.21 2286.30 2096.50 9.05
PBT 2495.80 2113.90 18.07 2495.80 2113.90 18.07 7504.90 10741.10 -30.13
TAX 830.00 713.20 16.38 830.00 713.20 16.38 2447.90 2137.40 14.53
Deferred Tax 30.00 118.70 -74.73 30.00 118.70 -74.73 208.40 164.60 26.61
PAT 1665.80 1400.70 18.93 1665.80 1400.70 18.93 5057.00 8603.70 -41.22
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 22.88 18.46 23.95 22.88 18.46 23.95 17.59 23.74 -25.88

Ipca Laboratories Share Price

1563.70 19.75 (1.28%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×